Type 1 Diabetes TrialNet (TrialNet) is an international network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes. TrialNet was established in response to the Surgeon General's Report Healthy People 2000. This report identified diabetes as a national health objective for the Nation. In response to the report, Congress created the Diabetes Research Working Group (DRWG) to develop a plan for diabetes research. A recommendation of the DRWG was to conduct additional research studies (clinical trials) to prevent type 1 diabetes. TrialNet was formed as the successor to the Diabetes Prevention Trial-Type 1 (DPT-1).

TrialNet conducts research in the following areas:
  • Pathway to Prevention Study: This study identifies individuals at high risk for developing diabetes. Individuals in this study may be eligible to participate in prevention studies. This study is also designed to study the natural history of disease progression.
  • Diabetes Prevention Studies: These studies test therapies that may delay or prevent the onset of type 1 diabetes in at risk individuals.
  • Diabetes Intervention Studies: These studies test therapies to preserve insulin producing cells in people recently diagnosed with type 1 diabetes.

To be notified about new TrialNet studies and study results, subscribe to the TrialNet e-newsletter. Past issues are available here.